CEVEC grants license to Biotest AG for production of tailor-made glycoproteins
Cologne, Germany, July 1, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), an expert for the production of glyco-optimized biopharmaceuticals, today announced that it has granted a license for its proprietary CAP®Go technology to Biotest AG for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients.
CEVEC INTRODUCES CAP®GO EXPRESSION SYSTEMS FOR SCALABLE PRODUCTION OF TAILOR-MADE GLYCOPROTEINS
Cologne, Germany, June 1, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), a global solution and service provider for the production of biopharmaceuticals based on a unique human cellular expression system, today announced the introduction of the technology platform CAP®Go for the fully scalable production of tailor-made glycosylated recombinant proteins, based on the Company’s proprietary CAP® Technology.
CEVEC ANNOUNCES APPOINTMENT OF
LIFE SIENCES INDUSTRY EXPERT FRANK UBAGS
AS CHIEF EXECUTIVE OFFICER
Cologne, Germany, April 17, 2015
CEVEC Pharmaceuticals GmbH (CEVEC), the provider of novel human cell expression systems, today announced the appointment of Frank Ubags as Chief Executive Officer starting immediately. He replaces Wolfgang Kintzel who is moving into the investor side of the life sciences industry. He will continue to serve as an advisor to CEVEC.
CEVEC: CAP® DERIVED RECOMBINANT C1 INHIBITOR MATCHES BERINERT® IN ANIMAL STUDY
Cologne, Germany, February 2, 2015
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).
CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than …
CEVEC INTRODUCES CMO SERVICES
FOR THE cGMP MANUFACTURING OF CAP-BASED
Cologne, Germany, September 23, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.